SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $5.94 and last traded at $5.9240, with a volume of 5409885 shares traded. The stock had previously closed at $5.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market cap of $856.79 million, a PE ratio of -21.41 and a beta of 2.18. The company’s 50 day simple moving average is $4.17 and its 200 day simple moving average is $2.66.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds have recently bought and sold shares of SLS. Caitong International Asset Management Co. Ltd boosted its position in SELLAS Life Sciences Group by 408.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 55,129 shares of the company’s stock worth $208,000 after purchasing an additional 44,296 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of SELLAS Life Sciences Group by 6.2% in the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after buying an additional 3,114 shares during the last quarter. Axxcess Wealth Management LLC grew its position in SELLAS Life Sciences Group by 121.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company’s stock valued at $133,000 after buying an additional 19,370 shares during the period. Beacon Pointe Advisors LLC purchased a new stake in SELLAS Life Sciences Group during the fourth quarter worth about $38,000. Finally, XTX Topco Ltd purchased a new stake in SELLAS Life Sciences Group during the fourth quarter worth about $447,000. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.